AGLE - Aeglea Biotherapeutics doses first patient in early-stage AGLE-177 Homocystinuria study

Aeglea BioTherapeutics (AGLE) announces the dosing of the first patient in the company's first-in-human Phase 1/2 clinical trial investigating AGLE-177 for the treatment of Homocystinuria, an rare inherited disorder of methionine metabolism.AGLE-177 is a novel engineered human enzyme therapy designed to lower the total level of homocysteine in the plasma.The elevated plasma homocysteine levels lead to a wide range of life-altering complications and reduced life expectancy in people with Homocystinuria.The multicenter, open label, dose escalation Phase 1/2 trial is anticipated to enroll 16-20 patients diagnosed with Homocystinuria aged 12 years or older at sites located in the United Kingdom and Australia. The primary endpoint of the study is to evaluate the safety and tolerability of AGLE-177.Aeglea anticipates providing a clinical update on the program prior to the end of 2021.

For further details see:

Aeglea Biotherapeutics doses first patient in early-stage AGLE-177 Homocystinuria study